1. Scrip
  2. >>Therapy Areas

Hunter to merge with Probiomics as it seeks partner for Phase II COPD vaccine

 
• By Sukaina Virji

Public unlisted Australian drug development company Hunter Immunology is recommending that its shareholders accept the takeover offer from listed biotech firm Probiomics.

Public unlisted Australian drug development company Hunter Immunology is recommending that its shareholders accept the takeover offer from listed biotech firm Probiomics.

The company's four largest shareholders, funds manager Chris Cuffe, investment group Intersuisse Biosciences and co-founders Dr Philip Comans and Professor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapeutic Category

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.